Pheochromocytoma and paraganglioma (PPGL) · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Track | standard |
|---|---|
| Linked regimen | None |
| ID | IND-SDH-CARRIER-SURVEILLANCE |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | DIS-PHEOCHROMOCYTOMA |
| Sources | SRC-NCCN-BCELL-2025 |
Notes
STUB — v0.2-B confirmed-carrier surveillance pathway (SDH-deficiency syndromes). Sibling — IND-SDH-CARRIER-INTENSIFIED (aggressive plan_track).
Used By
Actionability
BMA-METANEPHRINES-PHEO-VHL-MEN2-SURVEILLANCE- Plasma free metanephrines are the gold-standard biochemical test for pheochromocytoma and...
Indication
IND-SDH-CARRIER-INTENSIFIED- IND-SDH-CARRIER-INTENSIFIED
Red flag
RF-SDH-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic variant in one of the SDHx genes — SDHB...